Explore this week’s CC Journal Club

90‑sec video • 4‑min audio • paper abstracts

This week, 11 May 2025:

1. High-risk smoldering multiple myeloma: Daratumumab reduces progression risk by 51% and improves 5-year PFS.
2. High cardiovascular risk: Obicetrapib lowers LDL cholesterol by 29.9%.
3. Relapsed lymphoma: Armored anti-CD19 CAR T secreting IL-18 achieves 81% response rate after prior CAR T failure.
4. Post-TIA stroke: 12.8% within 5 years, 19.8% within 10 years.
5. Climate change: Majority of 2020 birth cohort will face unprecedented heat waves.